About NanoViricides (NYSEAMERICAN:NNVC)
NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-6.8
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-41.43%
Return on Assets-30.78%
NanoViricides (NYSEAMERICAN:NNVC) Frequently Asked Questions
What is NanoViricides' stock symbol?
NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."
How were NanoViricides' earnings last quarter?
NanoViricides Inc (NYSEAMERICAN:NNVC) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.03) earnings per share for the quarter. View NanoViricides' Earnings History.
When will NanoViricides make its next earnings announcement?
Are investors shorting NanoViricides?
NanoViricides saw a decrease in short interest in the month of December. As of December 29th, there was short interest totalling 459,345 shares, a decrease of 44.7% from the December 15th total of 830,252 shares. Based on an average daily volume of 186,490 shares, the short-interest ratio is currently 2.5 days. Approximately 0.9% of the company's stock are short sold.
Who are some of NanoViricides' key competitors?
Some companies that are related to NanoViricides include Bellerophon Therapeutics (BLPH), Agile Therapeutics (AGRX), Verona Pharma (VRP), Aeglea Bio Therapeutics (AGLE), RedHill Biopharma (RDHL), Trevena (TRVN), Ophthotech (OPHT), AcelRx Pharmaceuticals (ACRX), Motif Bio (MTFB), Arcturus Therapeutics (ARCT), ProQR Therapeutics (PRQR), Shield Therapeutics (STX), ADMA Biologics (ADMA), Gemphire Therapeutics (GEMP), Rocket Pharmaceuticals (RCKT), KemPharm (KMPH), Nexvet Biopharma (NVET) and MEI Pharma (MEIP).
Who are NanoViricides' key executives?
NanoViricides' management team includes the folowing people:
- Anil Diwan Ph.D., Chairman of the Board, President (Age 57)
- Eugene Seymour M.D., Chief Executive Officer, Director (Age 75)
- Meeta Vyas, Chief Financial Officer (Age 57)
- Milton Boniuk, Independent Director (Age 83)
- Stanley Glick CPA, Independent Director (Age 79)
- Mukund S. Kulkarni Ph.D., Independent Director (Age 68)
How do I buy NanoViricides stock?
Shares of NanoViricides can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NanoViricides' stock price today?
One share of NanoViricides stock can currently be purchased for approximately $1.02.
How big of a company is NanoViricides?
NanoViricides has a market capitalization of $64.60 million.
How can I contact NanoViricides?
NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137.
MarketBeat Community Rating for NanoViricides (NNVC)MarketBeat's community ratings are surveys of what our community members think about NanoViricides and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
NanoViricides (NYSEAMERICAN:NNVC) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
NanoViricides (NYSEAMERICAN:NNVC) Earnings History and Estimates Chart
NanoViricides (NYSEAMERICAN NNVC) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/25/2015||Q215||($0.05)||($0.03)||$1.75 million||$1.82 million||View||N/A|
NanoViricides (NYSEAMERICAN:NNVC) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for NanoViricides (NYSEAMERICAN:NNVC)
No dividend announcements for this company have been tracked by MarketBeat.com
NanoViricides (NYSEAMERICAN NNVC) Insider Trading and Institutional Ownership History
NanoViricides (NYSEAMERICAN NNVC) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/22/2015||Milton Boniuk||Director||Buy||25,000||$1.30||$32,500.00|| |
|9/11/2015||Milton Boniuk||Director||Buy||50,000||$1.02||$51,000.00|| |
|8/26/2015||Milton Boniuk||Director||Buy||50,000||$1.05||$52,500.00||1,705,391|| |
|7/8/2015||Milton Boniuk||Director||Buy||50,000||$1.58||$79,000.00|| |
|5/20/2015||Milton Boniuk||Director||Buy||50,000||$1.60||$80,000.00|| |
|5/8/2015||Milton Boniuk||Director||Buy||405,954||$2.58||$1,047,361.32|| |
|1/12/2015||Anil Diwan||Major Shareholder||Buy||14,000||$2.56||$35,840.00|| |
|1/6/2015||Milton Boniuk||Director||Buy||25,000||$2.60||$65,000.00|| |
|12/9/2014||Milton Boniuk||Director||Buy||50,000||$3.05||$152,500.00|| |
|7/17/2014||Milton Boniuk||Director||Buy||57,144||$3.50||$200,004.00|| |
|2/20/2014||Anil Diwan||Major Shareholder||Buy||50,000||$3.61||$180,500.00|| |
|10/21/2013||Anil Diwan||Major Shareholder||Sell||142,000||$5.29||$751,180.00|| |
NanoViricides (NYSEAMERICAN NNVC) News Headlines
NanoViricides (NYSEAMERICAN:NNVC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NanoViricides (NYSEAMERICAN:NNVC) Income Statement, Balance Sheet and Cash Flow Statement
NanoViricides (NYSEAMERICAN NNVC) Stock Chart for Sunday, January, 21, 2018